Keywords: بیماری پایدار; CI; confidence interval; CR; complete response; DC; disease control; OS; overall survival; PD; progressive disease; PR; partial response; RECIST; Response Evaluation Criteria in Solid Tumors; SD; stable disease; STS; soft tissue sarcoma; TARE; transarteri
مقالات ISI بیماری پایدار (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: بیماری پایدار; metastatic breast cancer; MBC; lobaplatin and gemcitabine; GL; lobaplatin and vinorelbine; NL; cisplatin and gemcitabine; GP; cisplatin and vinorelbine; NP; progression-free survival; PFS; overall survival; OS; response rate; RR; platinum-based compounds;
Keywords: بیماری پایدار; CR; complete response; DEE; drug-eluting embolic; ÎPBV; change in median parenchymal blood volume; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PBV; parenchymal blood volume; PD; progressive disease; PR;
Keywords: بیماری پایدار; APC; antigen presenting cell; APOBEC; apolipoprotein B mRNA editing enzyme catalytic polypeptide-like; BRCA1/2; breast cancer 1/2; BCSS; breast cancer specific survival; B2M; β-2-microglobulin; CAF; cancer associated fibroblast; CCL; chemokine ligand; CD
Keywords: بیماری پایدار; FDA; US Food and Drug Administration; BCG; Calmette and Guerin; DC; dendritic cell; APCs; antigen-presenting cells; TSAs; tumor specific antigens; TRA; tumor rejection antigen; gp96; glycoprotein of 96â¯kDa; CTLs; cytotoxic T cells; SEREX; serological an
Keywords: بیماری پایدار; kidney; carcinoma; renal cell; neoplasm metastasis; interleukin-2; molecular targeted therapy; CR; complete response; ECOG; Eastern Cooperative Oncology Group; HDIL-2; high dose IL-2; IL-2; interleukin-2; mRCC; metastatic RCC; OS; overall survival; PD; pr
Keywords: بیماری پایدار; AE; adverse event; AML; acute myeloid leukemia; APC; anaphase promoting complex; CLL; chronic lymphocytic leukemia; CPC; chromosomal passenger complex; CR; complete response; CRi; complete remission with incomplete blood count recovery; FDA; Food and Drug
Keywords: بیماری پایدار; MDS; Response; Stable disease; Hypomethylating agent
Keywords: بیماری پایدار; CR; complete response; CNR; contrast-to-noise ratio; GIST; gastrointestinal stromal tumor; PD; progressive disease; PDGFRA; platelet-derived growth factor receptor A; PET; positron-emission tomography; PFI; progression-free interval; PR; partial response;
Keywords: بیماری پایدار; BRAF; v-raf murine sarcoma viral oncogene homolog; MEK; MAP kinase-ERK kinase; KIT; V-KIT Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; PD-1/PD-L1; programmed death-1/ programmed death-1 li
Keywords: بیماری پایدار; BE; bland embolization; CI; confidence interval; GM-CSF; granulocyte-macrophage colony-stimulating factor; HR; hazard ratio; IL; interleukin; ORR; overall response rate; OS; overall survival; PFS; progression-free survival; PR; partial response; SD; sta
Keywords: بیماری پایدار; CR; complete response; EFS; event-free survival; LCR; local control rate; LFU; lost to follow-up; N; number of patients; ORR; overall response rate; OS; overall survival; PD; progressive disease; PNET; primitive neuroectodermal tumor; PR; partial response
Keywords: بیماری پایدار; AE; adverse effect; APC; antigen-presenting cells; CI; confidence interval; CP; carboplatin and paclitaxel; CR; complete response; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4; cuSCC; cutaneous squamous cell carcinoma; FDA; Food and Drug Administ
Keywords: بیماری پایدار; AJCC; American Joint Committee on Cancer; BMI; body mass index; CR; complete response; CSS; cause-specific survival; EBV; Epstein-Barr virus; FFLF; freedom from local failure; FFDF; freedom from distant failure; GORTEC; Oncology and Radiotherapy Group for
Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer
Keywords: بیماری پایدار; ALK; anaplastic lymphoma kinase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; BSA; body surface area; Ccr; creatinine clearance; CI; confidence interval; CR; complete response; CTCAE; common terminology criteria for adverse events; DCR;
A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease
Keywords: بیماری پایدار; ILD; interstitial lung disease; IPF; idiopathic pulmonary fibrosis; AE; acute exacerbation; AE-ILD; acute exacerbation of interstitial lung disease; NSCLC; non-small cell lung cancer; S-1; tegafur-gimeracil-oteracil potassium; CBDCA; carboplatin; RECIST;
Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma
Keywords: بیماری پایدار; CR; complete response; FDA; Food and Drug Administration; HR; hazard ratio; MPM; malignant pleural mesothelioma; mRECIST; modified pleural Response Evaluation Criteria in Solid Tumors; ORR; objective response rate; OS; overall survival; PD; progression of
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
Keywords: بیماری پایدار; AE; adverse event; ALK; anaplastic lymphoma kinase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; CI; confidence interval; CR; complete response; ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; HR; hazar
High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs
Keywords: بیماری پایدار; SSTR; somatostatin receptor; NEN; neuroendocrine neoplasms; SRS; somatostatin receptor scintigraphy; GI; gastrointestinal; GEP; gastroenteropancreatic; NET; neuroendocrine tumor; NEC; neuroendocrine carcinoma; PR; partial response; SD; stable disease; PD;
Diagnostic validation and interpretation of longitudinal circulating biomarkers using a biomarker response characteristic plot
Keywords: بیماری پایدار; BReC plot; biomarker response characteristic plot; CEA; carcinoembryonic antigen; Cyfra 21.1; cytokeratin 19 fragment; RECIST; response evaluation criteria in solid tumors; CR; complete remission; PR; partial remission; SD; stable disease; PD; progressive
Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST
Keywords: بیماری پایدار; ADC; apparent diffusion coefficient; CBR; clinical benefit response; CT; computed tomography; D; pure diffusion; DW; diffusion weighted; H-ADC; histogram-apparent diffusion coefficient; H-D; histogram-pure diffusion; H-PF; histogram-perfusion fraction; MR
CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin
Keywords: بیماری پایدار; CI; ConfidenceInterval; CT; ComputedTomography; CTTA; CT-TexturalAnalysis; DCR; Disease Control Rate; DNA; DeoxyribonucleicAcid; FDG-PET; Fludeoxyglucose-Positron Emission Tomography; Fig.; Figure; GIST; Gastrointestinal Stromal Tumor; NGLD; MNeighboring
Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines
Keywords: بیماری پایدار; NSCLC; non-small cell lung cancer; PBC; platinum-based chemotherapy; CR; complete response; PR; partial response; NC; no change; SD; stable disease; PD; progressive disease; ORR; objective response rate; DCR; Disease Control Rate; KPS; karnofsky performan
Bispecific antibodies for cancer therapy: A review
Keywords: بیماری پایدار; ADCC; antibody-dependent cell-mediated cytotoxicity; AE; adverse events; ALL; acute lymphoblastic leukemia; ALP; alkaline phosphatase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; B-ALL; B-cell acute lymphoblastic leukemia; BiTES; Bi-sp
Predictive role of GSTP1-containing exosomes in chemotherapy-resistant breast cancer
Keywords: بیماری پایدار; GSTP1; glutathione S-transferase P1; PD; progressive disease; SD; stable disease; PR; partial response; CR; complete response; TSG101; tumour susceptibility gene 101 protein; BCa; breast cancer; microRNA; miRNA; DNA; deoxyribonucleic acid; HSP70; heat sho
The Role of Dual-Phase Cone-Beam CT in Predicting Short-Term Response after Transarterial Chemoembolization for Hepatocellular Carcinoma
Keywords: بیماری پایدار; CI; confidence interval; CR; complete response; HCC; hepatocellular carcinoma; HU; Hounsfield unit; mRECIST; modified Response Evaluation Criteria in Solid Tumors; PD; progressive disease; PR; partial response; ROI; region of interest; SD; stable disease;
Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT
Keywords: بیماری پایدار; CR; complete response; HCC; hepatocellular carcinoma; LSF; lung shunt fraction; mRECIST; Modified Response Evaluation Criteria in Solid Tumors; NET; neuroendocrine tumor; PD; progressive disease; PR; partial response; SD; stable disease; SPECT; single pho
Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib
Keywords: بیماری پایدار; AFP; alpha fetoprotein; CI; confidence interval; DNA; deoxyribonucleic acid; EGF; epidermal growth factor; FGF; fibroblast growth factor; G-CSF; granulocyte colony-stimulating factor; HBV; hepatitis B virus; HCC; hepatocellular carcinoma; HR; hazard ratio
Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study
Keywords: بیماری پایدار; ALK; Anaplastic Lymphoma Kinase; BMI; body mass index; CCI; Charlson Comorbidity Index; CI; confidence interval; CR; complete response; CRISP; clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patien
Is Fractionated Gamma Knife Radiosurgery a Safe and Effective Treatment Approach for Large-Volume (>10 cm3) Intracranial Meningiomas?
Keywords: بیماری پایدار; Fractionation; Gamma Knife radiosurgery; Meningioma; BED; Biologically effective dose; FGKS; Fractionated Gamma Knife radiosurgery; GKS; Gamma Knife radiosurgery; MNG; Meningioma; MRI; Magnetic resonance imaging; PD; Progressive disease; PFS; Progression-
Quantification of Rac1 and Rac1b in serum of non small cell lung cancer by label free real time assay
Keywords: بیماری پایدار; NSCLC; Non Small Cell Lung Cancer; pre chemo; pre chemotherapy; Post chemo; post chemotherapy; SPR; surface plasmon resonance; EDC; N-ethyl-Nâ²-3diethylaminopropyl carbodiimide; NHS; N-hydroxysuccinimide; RU; response units; PVDF; polyvinylidene difluori
Initial Experience: Alleviation of Pain with Percutaneous CT-Guided Cryoablation for Recurrent Retroperitoneal Soft-Tissue Sarcoma
Keywords: بیماری پایدار; CR; complete response; PD; progressive disease; PFS; progression-free survival; PR; partial response; RPS; retroperitoneal soft-tissue sarcoma; RR; response rate; SD; stable disease; VAS; visual analog scale;
Multidisciplinary effort in treating children with hepatoblastoma in China
Keywords: بیماری پایدار; Hepatoblastoma; Pediatrics; Neoadjuvant chemotherapy; Surgery; Multidisciplinary team; AFP; α-fetoprotein; CCCG; Chinese Children's Cancer Group; CHIC; Children's Hepatic tumor International Collaboration; CI; confidence interval; COG; Children's Oncolog
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
Keywords: بیماری پایدار; AE; adverse event; CI; confidence interval; CR; complete response; CT; computed tomography; DCR; disease control rate; ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; FAS; full analysis set; HR; hazard ratio; ILD; interst
Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer
Keywords: بیماری پایدار; CTC; circulating tumor cell; FCMC; fluidic cell microarray chip; CM; cell microarray; NCCH; National Cancer Center Hospital; CICK; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital; CK; cytokeratin; PFS; progression free survival;
The role of miRNAs in drug resistance and prognosis of breast cancer formalin-fixed paraffin-embedded tissues
Keywords: بیماری پایدار; FFPE; formalin-fixed, paraffin-embedded; RECIST; Response Evaluation Criteria in Solid Tumors Group; HE; hematoxylin and eosin; PR; partial remission; SD; stable disease; PD; progressive disease; miRNA; Drug resistance; Breast cancer; FFPE;
Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria
Keywords: بیماری پایدار; CR; complete response, EASL = European Association for the Study of the Liver; HCC; hepatocellular carcinoma; MAA; macroaggregated albumin; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PET; positron emission tomography; PFS; progression
Combined Cisplatin-Based Chemoembolization and Radiation Therapy for Hepatocellular Carcinoma Invading the Main Portal Vein
Keywords: بیماری پایدار; BCLC; Barcelona Clinic Liver Cancer; CR; complete response; HCC; hepatocellular carcinoma; PD; progressive disease; PR; partial response; PV; portal vein; PVTT; portal vein tumor thrombosis; RT; radiation therapy; SD; stable disease;
Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization
Keywords: بیماری پایدار; ADC; apparent diffusion coefficient; AUC; area under the curve; CR; complete response; DEB; drug-eluting bead; DWI; diffusion-weighted imaging; EASL; European Association for the Study of the Liver; HCC; hepatocellular carcinoma; LRT; locoregional therapy
Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma
Keywords: بیماری پایدار; γ-δ; hematopoietic stem cell transplantation; primary cutaneous γδ T-cell lymphoma; subcutaneous panniculitis-like T-cell lymphoma; T-cell lymphoma; CHOP; cyclophosphamide, Adriamycin, vincristine, prednisone; CHOP-E; cyclophosphamide, Adriamycin, vin
Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens
Keywords: بیماری پایدار; LBD; ligand-binding domain; ERα; estrogen receptor α; NGS; next generation sequencing; ER+; ER-positive; AIs; aromatase inhibitors; MBC; metastatic breast cancer; ddPCR; droplet digital polymerase chain reaction; FFPE; formalin-fixed paraffin embedded;
Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer
Keywords: بیماری پایدار; HER; human epidermal growth factor receptor; NSCLC; non-small cell lung cancer; DLT; dose-limiting toxicity; MTD; maximum tolerated dose; EGFR-TKI; epidermal growth factor receptor-tyrosine kinase inhibitor; RECIST; response evaluation criteria in solid t
Targeting the TGFβ pathway for cancer therapy
Keywords: بیماری پایدار; Angiogenesis; Fibrosis; Metastasis; Microenvironment; TGFβ inhibitors; Tumor-stroma interactions; bFGF; basic fibroblast growth factor; bi-shRNAi; bi-functional short hairpin RNAi; CAF; cancer-associated fibroblasts; CR; complete response; CTGF; connecti
Lens culinaris agglutinin-reactive α-fetoprotein decline after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma predicts survival
Keywords: بیماری پایدار; HCC; hepatocellular carcinoma; AFP; α-fetoprotein; AFP-L3; Lens culinaris agglutinin-reactive α-fetoprotein; LCA; Lens culinaris agglutinin; Con A; concanavalin A; TACE; transcatheter arterial chemoembolization; Lectin dual-label TRFIAs; lectin dual-lab
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
Keywords: بیماری پایدار; Trastuzumab; Lapatinib; Chemotherapy-free; HER2-enriched; Microarray; Signature; CT; chemotherapy; total HER2; (H2T); p95HER2; (p95); PP; persistence on protocol; CR; complete remission; PR; partial remission; SD; stable disease; PD; progressive disease;
Genetics of rare mesenchymal tumors: Implications for targeted treatment in DFSP, ASPS, CCS, GCTB and PEComa
Keywords: بیماری پایدار; DFSP; dermatofibrosarcoma protuberans; ASPS; alveolar soft part sarcoma; CCS; clear cell sarcoma; GCTB; giant cell tumor of bone; PEComas; perivascular epithelioid cell neoplasm; PDGFRB; platelet-derived growth factor receptor, beta; MET; met proto-oncoge
Percutaneous Irreversible Electroporation for the Treatment of Colorectal Cancer Liver Metastases with a Proposal for a New Response Evaluation System
Keywords: بیماری پایدار; CEA; carcinoembryonic antigen; CI; confidence interval; CLM; colorectal liver metastasis; CR; complete response; EORTC; European Organization for the Research and Treatment of Cancer; FDG; [18F]fluorodeoxyglucose; HCC; hepatocellular carcinoma; IRE; irrev
Serum MicroRNA-210 as a Predictive Biomarker for Treatment Response and Prognosis in Patients with Hepatocellular Carcinoma undergoing Transarterial Chemoembolization
Keywords: بیماری پایدار; AFP; α-fetoprotein; BCLC; Barcelona Clinic Liver Cancer; CR; complete response; HCC; hepatocellular carcinoma; miRNA; microRNA; miR-210; microRNA-210; mRECIST; modified Response Evaluation Criteria in Solid Tumors; OS; overall survival; PD; progressive d
Yttrium-90 Radioembolization Stops Progression of Targeted Breast Cancer Liver Metastases after Failed Chemotherapy
Keywords: بیماری پایدار; BCLM; breast cancer liver metastasis; CA-27.29; cancer antigen 27.29; CI; confidence interval; HR; hazard ratio; mBC; metastatic breast cancer; OS; overall survival; PD; progressive disease; PET; positron emission tomography; PR; partial response; RECIST;
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer
Keywords: بیماری پایدار; CpG olignucleotide; Adjuvant; Infection; Cancer; Toll-like receptor; Ab; antibody; AE; adverse event; Ag; antigen; APC; Ag presenting cell; CTL; cytotoxic T cell; CR; complete response; DC; dendritic cell; GIA; growth inhibition assay; GMA; geometric mean